Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
Saved in:
| Title: | Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. |
|---|---|
| Authors: | Crouch ER; Virginia Pediatric Eye Center, Virginia Beach., Kraker RT; Jaeb Center for Health Research, Tampa, Florida., Wallace DK; Department of Ophthalmology, Indiana University School of Medicine, Indianapolis., Holmes JM; Mayo Clinic, Rochester, Minnesota., Repka MX; Wilmer Institute, Baltimore, Maryland., Collinge JE; Dean A. McGee Eye Institute, University of Oklahoma, Oklahoma City.; Now with Connecticut Children's Medical Center, Hartford, Connecticut., Bremer DL; Pediatric Ophthalmology Associates Inc, Columbus, Ohio., Gray ME; Cincinnati Children's Hospital, Cincinnati, Ohio., Smith HA; Department of Ophthalmology, Indiana University School of Medicine, Indianapolis., Steinkuller PG; Texas Children's Hospital, Houston. |
| Corporate Authors: | Writing Committee for Pediatric Eye Disease Investigator Group |
| Source: | JAMA ophthalmology [JAMA Ophthalmol] 2020 Jan 01; Vol. 138 (1), pp. 14-20. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print Cited Medium: Internet ISSN: 2168-6173 (Electronic) Linking ISSN: 21686165 NLM ISO Abbreviation: JAMA Ophthalmol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 31697304 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Crouch+ER%22">Crouch ER</searchLink>; Virginia Pediatric Eye Center, Virginia Beach.<br /><searchLink fieldCode="AU" term="%22Kraker+RT%22">Kraker RT</searchLink>; Jaeb Center for Health Research, Tampa, Florida.<br /><searchLink fieldCode="AU" term="%22Wallace+DK%22">Wallace DK</searchLink>; Department of Ophthalmology, Indiana University School of Medicine, Indianapolis.<br /><searchLink fieldCode="AU" term="%22Holmes+JM%22">Holmes JM</searchLink>; Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Repka+MX%22">Repka MX</searchLink>; Wilmer Institute, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Collinge+JE%22">Collinge JE</searchLink>; Dean A. McGee Eye Institute, University of Oklahoma, Oklahoma City.; Now with Connecticut Children's Medical Center, Hartford, Connecticut.<br /><searchLink fieldCode="AU" term="%22Bremer+DL%22">Bremer DL</searchLink>; Pediatric Ophthalmology Associates Inc, Columbus, Ohio.<br /><searchLink fieldCode="AU" term="%22Gray+ME%22">Gray ME</searchLink>; Cincinnati Children's Hospital, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Smith+HA%22">Smith HA</searchLink>; Department of Ophthalmology, Indiana University School of Medicine, Indianapolis.<br /><searchLink fieldCode="AU" term="%22Steinkuller+PG%22">Steinkuller PG</searchLink>; Texas Children's Hospital, Houston. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22Writing+Committee+for+Pediatric+Eye+Disease+Investigator+Group%22">Writing Committee for Pediatric Eye Disease Investigator Group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101589539%22">JAMA ophthalmology</searchLink> [JAMA Ophthalmol] 2020 Jan 01; Vol. 138 (1), pp. 14-20. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101589539 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2168-6173 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221686165%22">21686165 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Ophthalmol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31697304 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1001/jamaophthalmol.2019.4488 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 14 Titles: – TitleFull: Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Crouch ER – PersonEntity: Name: NameFull: Kraker RT – PersonEntity: Name: NameFull: Wallace DK – PersonEntity: Name: NameFull: Holmes JM – PersonEntity: Name: NameFull: Repka MX – PersonEntity: Name: NameFull: Collinge JE – PersonEntity: Name: NameFull: Bremer DL – PersonEntity: Name: NameFull: Gray ME – PersonEntity: Name: NameFull: Smith HA – PersonEntity: Name: NameFull: Steinkuller PG IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2020 Jan 01 Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 2168-6173 Numbering: – Type: volume Value: 138 – Type: issue Value: 1 Titles: – TitleFull: JAMA ophthalmology Type: main |
| ResultId | 1 |